Want to see JP:4574 full AI Analyst Report?
Taiko Pharmaceutical Co., Ltd. (4574) AI Stock Analysis
Taiko Pharmaceutical Co., Ltd.
(TSE/TYO:4574)
Taiko Pharmaceutical's overall score of 59 reflects a mixed outlook. The company's financial health is solid, with a strong balance sheet and improving profitability, providing a foundation for future growth. However, the stock is currently in a bearish technical trend, and valuation appears slightly rich, which tempers the overall attractiveness.
Taiko Pharmaceutical Co., Ltd. (4574) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 13.08B
- Dividend Yield
- 1.27%
- Average Volume (3M)
- 118.94K
- Price to Earnings (P/E)
- 19.0
- Beta (1Y)
- 0.66
- Revenue Growth
- 13.30%
- EPS Growth
- 66.38%
- Country
- Japan
- Employees
- 220
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Taiko Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Taiko Pharmaceutical Co.,Ltd. operates primarily in the pharmaceutical sector and the field of infection prevention. The company manufactures and distributes various over-the-counter medications, including its well-known Seirogan and Seirogan Toi-A b...
How the Company Makes Money
Taiko Pharmaceutical generates revenue primarily by selling pharmaceutical products. Key revenue streams typically include prescription and/or over-the-counter (OTC) drug sales to wholesalers, pharmacies, hospitals, and other healthcare providers, as...
Taiko Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
The company has returned to profitability with revenue growth and strong cash flow, while maintaining a robust balance sheet with low debt. However, revenue remains below peak levels and margins have softened.
Income Statement
68PositiveBalance Sheet
85Very PositiveCash Flow
75Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.62B | 6.40B | 6.29B | 6.12B | 5.04B | 10.72B |
| Gross Profit | 3.50B | 3.48B | 3.67B | 2.58B | 1.08B | 2.75B |
| EBITDA | 882.00M | 724.00M | 882.00M | -2.85B | -2.34B | -4.01B |
| Net Income | 688.00M | 923.00M | 898.00M | -3.61B | -4.89B | -9.59B |
Balance Sheet | ||||||
| Total Assets | 11.09B | 12.27B | 12.91B | 13.22B | 15.05B | 22.54B |
| Cash, Cash Equivalents and Short-Term Investments | 3.17B | 4.26B | 4.53B | 5.48B | 3.50B | 6.10B |
| Total Debt | 172.00M | 816.00M | 2.03B | 3.25B | 3.81B | 4.77B |
| Total Liabilities | 2.66B | 3.75B | 4.95B | 6.48B | 7.00B | 9.72B |
| Stockholders Equity | 8.43B | 8.52B | 7.96B | 6.74B | 8.04B | 12.81B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 523.00M | 205.00M | -421.00M | -2.08B | -3.19B |
| Operating Cash Flow | 0 | 814.00M | 362.00M | -307.00M | -1.99B | -1.59B |
| Investing Cash Flow | 0 | 142.00M | -5.00M | 1.17B | 190.00M | -1.62B |
| Financing Cash Flow | 0 | -1.23B | -1.18B | 1.54B | -997.00M | 3.96B |
Taiko Pharmaceutical Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4574, the sentiment is Positive. The current price of 260.00 is above the 20-day moving average (MA) of 259.70, above the 50-day MA of 259.40, and below the 200-day MA of 275.75, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 51.13 is Neutral, neither overbought nor oversold. The STOCH value of 24.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4574.
Taiko Pharmaceutical Co., Ltd. Peers Comparison
Overall Rating
JP:452481.5Outperform
JP:453864Neutral- JP:457459.4Neutral
JP:292959Neutral
JP:453946.5Neutral
JP:451245Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4524 | 82Outperform | JPY 8.95B | 11.40 | ― | 2.96% | 0.98% | 69.36% |
| JP:4538 | 64Neutral | JPY 18.48B | 8.21 | ― | 4.27% | 2.29% | ― |
| JP:4574 | 59Neutral | JPY 13.02B | 18.99 | ― | 1.27% | 13.30% | 66.38% |
| JP:2929 | 59Neutral | JPY 18.40B | 9.29 | ― | 3.46% | -3.12% | 406.78% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4539 | 47Neutral | JPY 5.47B | -44.12 | ― | 3.30% | 0.31% | -194.72% |
| JP:4512 | 45Neutral | JPY 10.52B | 30.73 | ― | 1.16% | 25.89% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4574 | Taiko Pharmaceutical Co., Ltd. | 260.00 | -15.00 | -5.45% | |
| JP:2929 | Pharma Foods International Co., Ltd. | 635.00 | -129.75 | -16.97% | |
| JP:4512 | Wakamoto Pharmaceutical Co., Ltd. | 303.00 | 16.42 | 5.73% | |
| JP:4524 | Morishita Jintan Co., Ltd. | 2195.00 | 126.34 | 6.11% | |
| JP:4538 | Fuso Pharmaceutical Industries,Ltd. | 2107.00 | 69.56 | 3.41% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1515.00 | -100.80 | -6.24% |
Taiko Pharmaceutical Co., Ltd. Corporate Events
Taiko Pharmaceutical Releases Q1 FY2026 Results and Full-Year Forecast
Taiko Pharmaceutical Co., Ltd. has released its consolidated financial results for the first quarter of the fiscal year ending December 31, 2026, providing an overview of its performance for the three-month period. The company also outlined performan...
Taiko Pharmaceutical Swings to Q1 Loss but Maintains 2026 Profit and Dividend Outlook
Taiko Pharmaceutical reported a sharp downturn for the first quarter ended March 31, 2026, with net sales falling 20.4% year on year to ¥916 million and a swing to an operating loss of ¥98 million. Profit attributable to owners of the paren...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026